经导管同期治疗复合型先天性心脏病的可行性  

作　　者：杜建文[1] 李旭东[1] 陈升恺[1] 李潮杰[1] 李创鹏[2] 杨华伟[2] 阮新民[3] 陈秋雄[3] 

机构地区：[1]广东省中医院珠海医院心胸外科,519015 [2]广东省中医院珠海医院心血管内科 [3]广东省中医院大学城分院心血管二科,510006

出　　处：《当代医学》2012年第18期3-4,共2页Contemporary Medicine

摘　　要：目的观察探讨经导管同期治疗复合型先天性心脏病的临床疗效,总结其临床可行性及意义。方法选取2006年3月～2012月3月在我院住院的31例复合型先天性心脏病的患者,均采取经导管同期治疗,对其临床病历资料进行回顾性分析。结果 31例患者皆为一次性治疗成功,治疗前后的跨肺动脉瓣平均压比较存在明显差异(P<0.05),具有统计学意义。结论经导管同期治疗复合型先天性心脏病的临床疗效理想,注意在操作中减少导丝或导管对ASD封堵装置的影响,减少并发症发生,以提高安全性。Objective To evaluate the simultaneous transcatheter therapy of combined congenital heart disease clinical curative effect, to sum up the clinical feasibility and significance. Methods From January 2008 to January 2012, 31 cases of combined congenital heart disease patients, are taking simultaneous transcatheter therapy, the clinical data were retrospectively analyzed. Results 31 cases are all disposable treatment success, before and after the treatment with ventricular angiography showed a maximum diameter of VSD, across the pulmonary valve average pressure is obvious difference （P〈0.05）, with statistical significance. Conclusion Simultaneous transcatheter therapy of combined congenital heart disease clinical curative effect is ideal, pay attention to in operation to reduce the guidewire or catheter on ASD plugging device, reduce complication, in order to improve the safety.

关 键 词：导管 同期治疗 复合型 先天性心脏病 

分 类 号：R654.2[医药卫生—外科学]